From Uncomplicated Alcoholism to Korsakoff's Syndrome

From Uncomplicated Alcoholism to Korsakoff's Syndrome: Clinical, Genetic, Neuropsychological and Brain Examinations

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01455207

Acronym

ALCOBRAIN

Enrollment

220

Registered

2011-10-19

Start date

2012-01-31

Completion date

2015-01-31

Last updated

2014-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholism, Alcohol Amnestic Disorder

Keywords

Magnetic Resonance Imaging, Positon Emission Tomography, Behavior

Brief summary

This research project aims to identify factors that contribute to the heterogeneity observed in neuroradiological and neuropsychological signs of chronic alcoholism. The investigators overarching hypothesis is that the heterogeneity of alcoholic consequences on brain structure and metabolism, and cognition is mainly related to individual differences in pattern of alcohol use, gene pool, nutritional status and history of withdrawal symptoms.

Interventions

BEHAVIORALNeuropsychological testing

assessment of memory, executive functions and ataxia

BIOLOGICALblood draw

hepatic markers, red blood markers and vitamin markers

GENETICgenetic testing

genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)

OTHERBrain imaging examination

MRI, DTI and PET examinations

Study design

Allocation

NON_RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Completed at least 8 years of education (primary school equivalent) * Age-normal corrected hearing and visual acuity

Exclusion criteria

* documented loss of consciousness of over 30 minutes, documented compound skull fracture, or clear neurological sequelae of head trauma * history of medical or neurological illness or trauma potentially affecting the CNS, e.g., stroke, multiple sclerosis, epilepsy, psychosurgery, insulin coma. * active tuberculosis or history of or any malignancy requiring chemotherapy * history of schizophrenia or bipolar disorder * metal implantation (e.g., pacemakers) or other factors that preclude MRI scanning for subjects selected for the neuroimaging examination * meet DSM-IV criteria for current (past 3 months) other Substance Abuse * met DSM-IV criteria for other Substance Dependence * Have used other substances more than 5 times in the past month

Design outcomes

Primary

Measure	Time frame
Evidence of brain dysfunctioning measured by neuropsychological testing and brain examination(MRI and PET)	one year

Secondary

Measure	Time frame
treatment outcomes (sobriety or relapse)	one year

Countries

France

Contacts

Primary ContactJulien Chavant, MA

memoire-recherche.caen@inserm.fr2 31 06 54 95

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026